Physician profile
Mary E Carroll
NPI 1730153636
$2,148.10
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $939 · 2020: $548 · 2021: $390 · 2022: $271.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $520.37 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $461.55 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $382.53 | 2019-2022 | |
| Novo Nordisk INC | $343.44 | 2019-2022 | |
| Pfizer INC. | $108.06 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $90.41 | 2021-2022 | |
| Abbvie INC. | $62.69 | 2022 | |
| Abbott Laboratories | $43.98 | 2019 | |
| Merck Sharp & Dohme LLC | $37.47 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.66 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.98 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.43 | 2019 | |
| Allergan, INC. | $14.64 | 2020 | |
| Glaxosmithkline, LLC. | $13.89 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.